Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Experts Preview Anticipated HER2-Positive Breast Cancer Data Ahead of SABCS 2025

December 4th 2025

Leading experts highlight key HER2-positive studies ahead of SABCS 2025.

Dr Raab on Continued Investigation of Teclistamab Plus Daratumumab-Based Induction in Myeloma

December 2nd 2025

Marc S. Raab, MD, discusses future avenues for the investigation of teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.

ctDNA and MRD Advance Toward Clinical Integration in Lymphoma

December 1st 2025

Sarah Rutherford, MD, discusses emerging roles for ctDNA and MRD in lymphoma, highlighting surveillance value, personalized assays, and evolving adoption.

Emerging Immunotherapy and Precision Medicine Strategies Take Aim at PDAC Treatment Resistance

November 30th 2025

Jose Trevino, MD, discusses how immunotherapy and precision medicine approaches may advance treatment for patients with immune-resistant PDAC.

Dr Desai on the Use of JAK Inhibitors in Myeloproliferative Neoplasms

November 28th 2025

Ruchi J. Desai, MD, discusses the current standing of JAK inhibitors in the treatment landscape of myeloproliferative neoplasms.

Advancing Early Detection and Therapeutic Innovation Remain Critical in Pancreatic Ductal Adenocarcinoma

November 28th 2025

Jose Trevino, MD, discusses unmet needs in PDAC, highlighting early detection and multidisciplinary care amid Pancreatic Cancer Awareness Month.

Dr Leal on Clinical Considerations Surrounding the Diagnosis of LEMS in Patients With Lung Cancer

November 26th 2025

Ticiana Leal, MD, discusses clinical considerations surrounding the diagnosis of LEMS in patients with lung cancer.

Dr Tinajero on the Role of Pharmacists in Treatment Planning and Management in CML

November 26th 2025

Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.

Dr Desai on Notable Ongoing Studies in Myeloproliferative Neoplasms

November 26th 2025

Ruchi J. Desai, MD, discusses several notable ongoing studies examining agents for the treatment of patients with myeloproliferative neoplasms.

Modest Efficacy Outcomes Necessitate Broader Clinical Considerations for Later-Line Treatment Selection in Refractory CRC

November 26th 2025

Tiago Biachi, MD, PhD, reviews how data from the CORRECT, SUNLIGHT, and FRESCO trials inform later-line treatment selection in refractory mCRC.

T-DM1 Displays a Lower Cardiotoxicity Risk vs Other HER2-Targeted Regimens in HER2+ Breast Cancer

November 26th 2025

T-DM1 showed the lowest LVEF decline vs other HER2-targeted regimens, underscoring key differences in cardiac safety.

Cevostamab-Based Combos Could Represent Next Bispecific Antibody Approach in R/R Myeloma

November 25th 2025

Joshua Richter, MD, discusses the evaluation of the FcRH5 x CD3 bispecific antibody in multiple myeloma.

Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD

November 25th 2025

Daniel Spratt, MD, discusses key updates to the National Comprehensive Cancer Network Guidelines for prostate cancer.

European Commission Approves Liso-Cel for R/R Mantle Cell Lymphoma

November 25th 2025

Liso-cel was approved in the EU for relapsed/refractory MCL after at least 2 lines of therapy, including a BTK inhibitor.

Subcutaneous Toripalimab Plus Chemo Meets PK End Points in Recurrent/Metastatic Nonsquamous NSCLC

November 25th 2025

Subcutaneous toripalimab generated non-inferior efficacy and safety outcomes vs the IV formulation in recurrent/metastatic non squamous NSCLC.

Dr Raab on Safety and Infection Prophylaxis With Daratumumab-Based Induction Regimens in Myeloma

November 25th 2025

Marc S. Raab, MD, outlines the safety profile of teclistamab plus Dara-VRd in newly diagnosed multiple myeloma from the MajesTEC-5 trial.

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma

November 24th 2025

INDIGO TGR analyses showed vorasidenib markedly slowed tumor growth and improved PFS and TTNI vs placebo in IDH1/2-mutant grade 2 glioma.

FDA Grants Fast Track Designation to AVZO-103 for Urothelial Cancer After Prior Enfortumab Vedotin

November 24th 2025

The FDA granted fast track designation to AVZO-103 for urothelial cancer previously treated with enfortumab vedotin.

Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

November 24th 2025

Marc S. Raab, MD, discusses evaluating teclistamab–based induction regimens in patients with newly diagnosed multiple myeloma

Sacituzumab Tirumotecan Plus Pembrolizumab Improves PFS in PD-L1+ Advanced NSCLC

November 24th 2025

Sacituzumab tirumotecan plus pembrolizumab improved PFS as first-line treatment in PD-L1–positive advanced NSCLC.